



PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	08/444,790-Conf. #5612
Filing Date	May 19, 1995
First Named Inventor	Manfred Brockhaus
Art Unit	1646
Examiner Name	Z. Howard
Attorney Docket Number	01017/40451B

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A64	5,428,130	06-27-1995		
	A65	5,040,791			
	A66	6,024,007			
				Patent Documents A65 and A66	

WITHDRAWN BY USPTO

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	f ^o
		Country Code* - Number* - Kind Code* (if known)	MM-DD-YYYY			
	B42	EP-0 394 827	10-31-1990			

*EXAMINER: Include if reference consideration whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Initial copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 001.04. *Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.15 if possible. *Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	†
	C157	FOLKS et al., Tumor necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone, PNAS, 86:2365-8 (1989).	
	C158	LEE, Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase, Science, 239:1288-1291 (1988).	
	C159	MORELAND et al., Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein, New England Journal of Medicine, 337:141-147 (1997).	
	C160	SANDBORN et al., Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterol., 121:1088-94 (2001).	
	C161	WOZNEY, Using purified protein to clone its genes, Methods in Enzymology, 182:738-751 (1990).	
	C162	Inflammation & Infection: Rheumatoid Arthritis, Drug & Market Development, 67-70 (2003).	
	C163	Letter to the EPO with new Auxiliary request 3 in appeal proc. against EP 0 471 701. 12/31/01	
	C164	Notification of the Examiner during the prosecution of EP 99100703.0. 10/24/00	
	C165	Zavoico, Drug & Market Development, 10(7):235-243 (1999).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Zachary Howard/	Date Considered	08/02/2011
-----------------------	------------------	--------------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./